Trinity Biotech
Market Cap
US$34.3m
Last Updated
2019/06/19 23:46 UTC
Data Sources
Company Financials +
Executive Summary
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe.
Snowflake
Fundamentals
Fair value with mediocre balance sheet.
Risks
- Trinity Biotech has significant price volatility in the past 3 months.
- Trinity Biotech is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has Trinity Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-9.9%
NasdaqGS:TRIB
2.2%
US Medical Equipment
1.6%
US Market
1 Year Return
-66.3%
NasdaqGS:TRIB
16.1%
US Medical Equipment
2.8%
US Market
TRIB underperformed the Medical Equipment industry which returned 14.6% over the past year.
TRIB underperformed the Market in United States of America which returned 2.3% over the past year.
Share holder returns
| TRIB | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.9% | 2.2% | 1.6% |
| 30 Day | -36.9% | 8.9% | 2.5% |
| 90 Day | -44.2% | 3.5% | 2.2% |
| 1 Year | -66.3%-66.3% | 17.1%16.1% | 5.0%2.8% |
| 3 Year | -85.0%-85.0% | 74.5%64.3% | 48.3%38.4% |
| 5 Year | -92.8%-92.9% | 126.0%99.5% | 57.8%40.3% |
Price Volatility Vs. Market
How volatile is Trinity Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
Are Trinity Biotech plc's (NASDAQ:TRIB) Interest Costs Too High?4 months ago | Simply Wall St
Could The Trinity Biotech plc (NASDAQ:TRIB) Ownership Structure Tell Us Something Useful?5 months ago | Simply Wall St
Trinity Biotech plc (NASDAQ:TRIB): What Does Its Beta Value Mean For Your Portfolio?Valuation
Is Trinity Biotech undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Trinity Biotech's share price is below the future cash flow value, and at a moderate discount (> 20%).
Trinity Biotech's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Trinity Biotech is loss making, we can't compare its value to the US Medical Equipment industry average.
Trinity Biotech is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Trinity Biotech, we can't assess if its growth is good value.
Price Based on Value of Assets
Trinity Biotech is good value based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Trinity Biotech expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
6.2%
Forecasted annual revenue growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Trinity Biotech's revenue is expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
Unable to determine if Trinity Biotech is high growth as no earnings estimate data is available.
Trinity Biotech's revenue growth is positive but not above the United States of America market average.
Unable to compare Trinity Biotech's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Trinity Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Trinity Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Trinity Biotech performed over the past 5 years?
-55.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Trinity Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Trinity Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Trinity Biotech's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Trinity Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Trinity Biotech has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Trinity Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Trinity Biotech's financial position?
Financial Position Analysis
Trinity Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Trinity Biotech's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Trinity Biotech's level of debt (185.5%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (0% vs 185.5% today).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Trinity Biotech has sufficient cash runway for more than 3 years based on current free cash flow.
Trinity Biotech has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -23% each year.
Next Steps
Dividend
What is Trinity Biotech's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Trinity Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Trinity Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Trinity Biotech has not reported any payouts.
Unable to verify if Trinity Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Trinity Biotech has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Trinity Biotech's salary, the management and board of directors tenure and is there insider trading?
10.6yrs
Average board tenure
CEO
Ronan O’Caoimh (62yo)
10.7yrs
Tenure
US$585,000
Compensation
Mr. Ronan O'Caoimh co-founded Trinity Biotech PLC in June 1992 and has been its Chief Executive Officer since October 2008. Mr. O'Caoimh served as Chief Executive Officer of Trinity Biotech PLC from March ...
CEO Compensation Analysis
Ronan's remuneration is about average for companies of similar size in United States of America.
Ronan's compensation has been consistent with company performance over the past year, both up more than 20%.
Board Age and Tenure
10.6yrs
Average Tenure
63yo
Average Age
The average tenure for the Trinity Biotech board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
No 3 month insider trading information.
Ownership Breakdown
Management Team
Ronan O’Caoimh (62yo)
Co-Founder
- Tenure: 10.7yrs
- Compensation: $585.00k
Jim Walsh (60yo)
Executive Director
- Compensation: $9.00k
Kevin Tansley (47yo)
CFO, Company Secretary & Executive Director
- Tenure: 11.6yrs
- Compensation: $523.00k
Board Members
Clint Severson (70yo)
Non-Executive Director
- Tenure: 10.6yrs
- Compensation: $75.00k
Denis Burger (74yo)
Non-Executive Director & Lead Director
Ronan O’Caoimh (62yo)
Co-Founder
- Tenure: 24.1yrs
- Compensation: $585.00k
Jim Walsh (60yo)
Executive Director
- Tenure: 12.4yrs
- Compensation: $9.00k
Jim Merselis (64yo)
Non-Executive Director
- Tenure: 10.3yrs
- Compensation: $75.00k
Kevin Tansley (47yo)
CFO, Company Secretary & Executive Director
- Tenure: 2.8yrs
- Compensation: $523.00k
Company Information
Trinity Biotech plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Trinity Biotech plc
- Ticker: TRIB
- Exchange: NasdaqGS
- Founded: 1992
- Industry: health care equipment
- Sector: healthcare
- Market Cap: US$34.279m
- Shares outstanding: 20.90m
- Website: Click here
Number of Employees
Location
- Trinity Biotech plc
- IDA Business Park
- Bray
- Co. Wicklow
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TRIB | NasdaqGS (Nasdaq Global Select) | Yes | ADR EACH REPR 4 CLS'A'ORD USD0.019 | US | USD | Oct 1992 |
| TRBA | DB (Deutsche Boerse AG) | Yes | ADR EACH REPR 4 CLS'A'ORD USD0.019 | DE | EUR | Oct 1992 |
Biography
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Afr ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/06/19 23:46 |
| End of Day Share Price | 2019/06/19 00:00 |
| Earnings | 2019/03/31 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.